Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to equity ratio high or low?
The debt to equity ratio of 0.02 is 18% above its 5-year average of 0.01, around the middle of its 5-year range (0.01–0.03).
As of the fiscal period ended Tuesday, June 30, 2026. 9.15% below its 12-month average of 0.02.
Reported quarterly debt to equity ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 0.02.
DEBT TO EQUITY RATIO
0.02
DEBT TO EQUITY RATIO AVG TTM
0.02
DEBT TO EQUITY RATIO AVG 3Y
0.02
DEBT TO EQUITY RATIO AVG 5Y
0.01
DEBT TO EQUITY RATIO AVG 10Y
0.01
DEBT TO EQUITY RATIO AVG 15Y
N/A
DEBT TO EQUITY RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-9.15%
CURRENT VS 3Y AVG
-5.25%
CURRENT VS 5Y AVG
+17.61%
CURRENT VS 10Y AVG
+55.15%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11
median of 764 covered companies
CURRENT VS SECTOR MEDIAN
-84.60%
vs the sector median at left
Rhythm Pharmaceuticals, Inc.
Market Cap
$6.20B
Debt to Equity Ratio
0.02
TTM Avg
0.02
3Y Avg
0.02
5Y Avg
0.01
Market Cap
$5.91B
Debt to Equity Ratio
1.17
TTM Avg
0.23
3Y Avg
0.15
5Y Avg
0.27
Market Cap
$5.89B
Debt to Equity Ratio
0.06
TTM Avg
0.08
3Y Avg
0.11
5Y Avg
0.11
Market Cap
$6.49B
Debt to Equity Ratio
84.54
TTM Avg
74.29
3Y Avg
41.61
5Y Avg
30.23
Market Cap
$6.51B
Debt to Equity Ratio
0.48
TTM Avg
0.57
3Y Avg
0.80
5Y Avg
0.68
Market Cap
$6.53B
Debt to Equity Ratio
4.77
TTM Avg
1.04
3Y Avg
0.53
5Y Avg
0.36
Market Cap
$5.81B
Debt to Equity Ratio
1.57
TTM Avg
0.74
3Y Avg
0.65
5Y Avg
0.49
| NAME | MARKET CAP | DEBT TO EQUITY RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rhythm Pharmaceuticals, Inc. (RYTM) | $6.20B | 0.02 | 0.02 | 0.02 | 0.01 |
| GRAIL Inc. (GRAL)vs › | $5.99B | 0.04 | 0.04 | 0.03 | 0.04 |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.91B | 1.17 | 0.23 | 0.15 | 0.27 |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.89B | 0.06 | 0.08 | 0.11 | 0.11 |
| Amneal Pharmaceuticals, Inc. (AMRX)vs › | $6.49B | 84.54 | 74.29 | 41.61 | 30.23 |
| Immunovant, Inc. (IMVT)vs › | $6.50B | 0.00 | 0.00 | 0.00 | 0.00 |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 0.48 | 0.57 | 0.80 | 0.68 |
| Hims & Hers Health, Inc. (HIMS)vs › | $6.53B | 4.77 | 1.04 | 0.53 | 0.36 |
| Kodiak Sciences Inc. (KOD)vs › | $5.81B | 1.57 | 0.74 | 0.65 | 0.49 |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.80B | 0.01 | 0.02 | 0.02 | 0.02 |
Debt/Equity
0.02
Current Ratio
3.45
Debt to Equity measures financial leverage by comparing total debt to shareholders' equity.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO EQUITY RATIO |
|---|---|
| 2026-06-30 | 0.02 |
| 2026-03-31 | 0.02 |
| 2025-12-31 | 0.01 |
| 2025-09-30 | 0.01 |
| 2025-06-30 | 0.03 |
| 2025-03-31 | 0.02 |
| 2024-12-31 | 0.02 |
| 2024-09-30 | 0.03 |
| 2024-06-30 | 0.02 |
| 2024-03-31 | 0.02 |
| 2023-12-31 | 0.01 |
| 2023-09-30 | 0.01 |
| 2023-06-30 | 0.01 |
| 2023-03-31 | 0.01 |
| 2022-12-31 | 0.01 |
| 2022-09-30 | 0.01 |
| 2022-06-30 | 0.01 |
| 2022-03-31 | 0.01 |
| 2021-12-31 | 0.01 |
| 2021-09-30 | 0.01 |
| 2021-06-30 | 0.01 |
| 2021-03-31 | 0.01 |
| 2020-12-31 | 0.02 |
| 2020-09-30 | 0.02 |
| 2020-06-30 | 0.01 |
| 2020-03-31 | 0.01 |
| 2019-12-31 | 0.01 |
| 2019-09-30 | 0.02 |
| 2019-06-30 | 0.02 |
| 2019-03-31 | 0.02 |
| 2018-12-31 | 0.00 |
| 2018-09-30 | 0.00 |
| 2018-06-30 | 0.00 |
| 2018-03-31 | 0.00 |
| 2017-12-31 | 0.00 |
| 2017-09-30 | 0.00 |
| 2017-06-30 | 0.00 |
| 2017-03-31 | 0.00 |
| 2016-12-31 | 0.00 |
| 2016-09-30 | 0.00 |
| 2016-06-30 | 0.00 |
| 2016-03-31 | 0.00 |
| 2015-12-31 | 0.00 |
| 2015-09-30 | 0.00 |
| 2015-06-30 | 0.00 |
| 2015-03-31 | 0.00 |
| 2014-12-31 | 0.00 |
| 2014-09-30 | 0.00 |
| 2014-06-30 | 0.00 |
| 2014-03-31 | 0.00 |
| 2013-12-31 | 0.00 |
